How Does Muscular Dystrophy Affect the Brain?

Muscular dystrophy is usually thought of as a disease of muscles, but several forms directly involve the brain. The most studied example is Duchenne muscular dystrophy, where the same protein missing from muscles, dystrophin, also plays roles at brain synapses and in blood-brain barrier integrity. The result is that a significant proportion of boys with Duchenne show cognitive differences, particularly in working memory, and face elevated rates of ADHD, anxiety, and autism spectrum traits. Duchenne is not the only form with brain involvement, though, and the mechanisms differ strikingly across types of muscular dystrophy.

Dystrophin Is Not Just a Muscle Protein

The gene that causes Duchenne and Becker muscular dystrophies is enormous, one of the largest in the human genome. It produces not just the full-length dystrophin protein used in muscles but several shorter versions, called isoforms, that are active in the brain. The key brain isoforms include Dp427c (the cortical form), Dp140, and Dp71. Each is produced from a different internal starting point on the gene, and each shows a distinct pattern of when and where it appears during brain development.

Research mapping dystrophin expression in the human brain across the lifespan has found that Dp140 is highly expressed during early to mid-fetal development but drops sharply after birth, though it persists at low levels in the cerebellum and cortex into adulthood.¹ Dp71, the smallest and most abundant brain isoform, stays highly expressed from fetal life through adulthood with little regional preference. More recent work has also detected dystrophin transcripts in motor neurons and confirmed that different isoforms can be co-expressed within single neurons, including in inhibitory and excitatory neurons across the cortex, hippocampus, and cerebellum.²

This matters because a boy’s specific mutation on the dystrophin gene determines which isoforms he loses. A mutation near the beginning of the gene might knock out only the full-length muscle form, leaving the brain isoforms intact. A mutation further downstream can wipe out Dp140 or Dp71 as well. That distinction turns out to be one of the strongest predictors of how much a person’s cognition is affected.

The Cognitive Profile in Duchenne

On average, boys with Duchenne muscular dystrophy score roughly one standard deviation below the population mean on full-scale IQ tests.³ That does not mean every boy is intellectually disabled; the range is wide, and many score well within normal limits. But a consistent pattern emerges in the data: working memory is the most reliably impaired domain.⁴ Verbal short-term memory and verbal recall also tend to be weaker than other skills. These deficits appear to be present from early childhood and do not worsen with age, which suggests they are neurodevelopmental rather than neurodegenerative.⁵

This is an important distinction. The muscle disease in Duchenne is progressive: strength declines over time, and the condition is ultimately life-limiting. But the cognitive profile is generally stable. A boy who struggles with working memory at age six will likely have a similar pattern at sixteen. The brain manifestations are better understood as a feature of how the brain developed without certain dystrophin isoforms, not as ongoing brain damage.

Where the Mutation Falls Matters

Not all Duchenne mutations carry the same cognitive risk. The clearest dividing line is whether the mutation disrupts the Dp140 isoform. Studies consistently find that boys whose mutations knock out Dp140 have significantly lower IQ scores and broader cognitive difficulties compared with boys whose mutations spare it.⁶ One analysis found that mutations hitting the Dp140 promoter and coding regions had a more profound effect on IQ than those affecting only the untranslated region upstream, suggesting that even partial loss of Dp140 production matters less than complete loss.⁷

The pattern goes beyond overall IQ. Boys with mutations in the distal part of the gene, affecting Dp140, tend to show specific weaknesses in visuospatial processing and visual memory that boys with more upstream mutations do not share. The distal-mutation group also shows greater impairment in understanding complex sentence structures.³ This means that knowing someone has Duchenne is not enough to predict their cognitive profile; you need to know which part of the gene is affected.

ADHD, Anxiety, and Other Neurobehavioral Conditions

Beyond IQ and memory, boys with Duchenne face elevated rates of several neurodevelopmental and psychiatric conditions. A systematic review and meta-analysis across available studies found that roughly 18% meet criteria for ADHD, 24% for anxiety disorders, about 12% for obsessive-compulsive disorder, 11% for depression, and 7% for autism spectrum disorder.⁸ All of these rates exceed what you’d expect in the general population.

It can be tempting to attribute anxiety or depression in Duchenne to the emotional burden of living with a severe physical disability. That is undoubtedly part of the picture. But the rates of ADHD and autism spectrum traits, which are neurodevelopmental conditions present from early life, point toward a biological contribution from dystrophin loss in the brain. An earlier questionnaire-based study of 351 males with Duchenne found ADHD in about 12% and autism spectrum disorder in about 3%, both higher than population baselines.⁹ The meta-analysis estimates are higher, likely reflecting broader screening methods and increased awareness over time.

The practical takeaway is that behavioral and emotional screening should be routine in Duchenne care. These conditions are treatable. A descriptive study of psychopharmaceutical treatment in 52 patients with Duchenne found that over half of those treated with methylphenidate for ADHD symptoms showed marked improvement, and about 40% of those treated with fluoxetine for mood symptoms improved as well.¹⁰ A separate small study of short-acting methylphenidate in boys with both Duchenne and ADHD reported improvements in concentration, impulsivity, and distractibility in the majority of patients, with no major side effects.¹¹

What Brain Imaging Reveals

MRI studies of boys with Duchenne show measurable differences in brain structure. Compared with age-matched healthy controls, boys with Duchenne have smaller total brain volume, reduced gray matter, and changes in white matter integrity.¹² Diffusion imaging of the corpus callosum, the bundle of fibers connecting the two hemispheres, has found reduced integrity specifically in its rear portion, and the degree of that reduction correlates with verbal IQ scores.¹³

Functional MRI adds another layer. When researchers looked at resting-state brain networks in boys with Duchenne, they found abnormal patterns specifically in the default mode network, a set of brain regions active during rest, mind-wandering, and internal thought. The boys showed hyperconnectivity within this network and connections to areas outside it that are not typically involved, while other major networks (visual, executive control) looked normal.¹⁴ The default mode network is implicated in attention regulation, working memory, and information processing, which aligns well with the cognitive profile described in behavioral testing.

Synaptic Disruption and the Blood-Brain Barrier

The mechanism by which missing dystrophin alters brain function centers on synapses, the junctions where neurons communicate. In the brain, dystrophin and its associated protein dystroglycan help anchor receptors for GABA, the brain’s main inhibitory neurotransmitter, at the right spots on neurons. Without dystrophin, the clustering of these GABA receptors is disrupted.¹⁵ In the dystrophin-deficient mouse model (the mdx mouse), this leads to abnormal signaling at inhibitory synapses and exaggerated responses at excitatory synapses in the hippocampus, a region critical for learning and memory.¹⁶

Dystroglycan also plays a role in a form of synaptic self-regulation called homeostatic plasticity, where inhibitory synapses strengthen in response to chronic overexcitement. When dystroglycan is knocked down experimentally, this safety mechanism fails, leaving neurons unable to properly calibrate their own activity levels.¹⁷

There is also evidence that the blood-brain barrier itself is compromised. In the mdx mouse, brain blood vessels show open gaps between endothelial cells, swollen support cells, and a roughly 60% reduction in key structural proteins that normally keep the barrier sealed. When a tracer dye was injected, it leaked extensively into surrounding brain tissue in the dystrophic mice while staying confined to blood vessels in healthy controls.¹⁸ Whether this blood-brain barrier breakdown translates fully to humans remains an active question, but it offers another route through which dystrophin loss could affect brain function.

Becker Muscular Dystrophy and the Brain

Becker muscular dystrophy involves the same gene as Duchenne but produces a partially functional dystrophin protein rather than none at all. The muscle disease is milder, and a reasonable assumption would be that the brain is spared. That assumption is only partly correct. A systematic review found high rates of cognitive impairment in Becker patients, with specific involvement across several cognitive domains. Unlike Duchenne, verbal skills tend to be better preserved, but executive function, the ability to plan, multitask, and flexibly shift between tasks, is a notable weakness.¹⁹

When researchers compared Becker patients directly with patients who had a different, non-dystrophin-related muscular dystrophy (limb-girdle muscular dystrophy), the Becker group performed significantly worse on dual-task testing, which requires doing two cognitive things at once.²⁰ That comparison is useful because it controls for the general burden of living with muscle disease; the Becker-specific deficit in executive function points toward a biological effect of partial dystrophin loss rather than a psychological response to disability. As in Duchenne, loss of the Dp140 or Dp71 isoforms appears to be the main driver of more severe cognitive and psychiatric effects in Becker patients.¹⁹

Myotonic Dystrophy and the Brain

Myotonic dystrophy types 1 and 2 (DM1 and DM2) affect the brain through an entirely different mechanism than Duchenne and Becker. In these conditions, the genetic error produces abnormally long stretches of repetitive RNA that accumulate inside cell nuclei. These toxic RNA clusters grab and trap proteins that normally regulate how other genes are processed, disrupting the splicing of hundreds of downstream targets in the brain.²¹ Among the casualties is tau, a protein better known for its role in Alzheimer’s disease; in the myotonic dystrophy brain, abnormal fetal forms of tau persist into adulthood.

This RNA toxicity also damages astrocytes, the star-shaped support cells that maintain the brain’s structural scaffolding. Research has shown that the toxic RNA alters astrocyte shape, adhesion, and migration in both mouse brains and human cell models.²²

The clinical picture reflects this widespread disruption. The core brain symptoms of DM1 are cognitive deficits, excessive daytime sleepiness, and apathy, and research links these directly to white matter damage in the brain rather than to the emotional stress of chronic illness.²³ The sleepiness is particularly striking and has been called the hallmark neurological symptom of DM1. Evidence increasingly supports the view that it arises from a central dysfunction in sleep regulation within the brainstem, not merely from poor sleep caused by breathing difficulties.²⁴

Brain imaging in DM1 patients reveals white matter hyperintensities, bright spots on MRI that indicate damage to the brain’s wiring. These lesions appear in virtually all patients and grow with age. Their volume and number correlate with reduced cognitive efficiency, including slower processing speed and lower IQ scores.²⁵ Both DM1 and DM2 patients show gray matter reduction in the frontal and parietal lobes, reduced hippocampal volume linked to memory deficits, and decreased brain metabolism in frontal and temporal regions.²⁶ All of these abnormalities are present in both types but are more pronounced in DM1.

DM2, though similar in pattern, tends to be milder. While almost all DM1 patients show cognitive impairment across multiple domains, only about a third of DM2 patients do, and the deficits that appear tend to involve executive function and memory in older patients or those with more severe muscle weakness.²⁷

Congenital Muscular Dystrophies and Brain Malformation

A group of congenital muscular dystrophies linked to problems with dystroglycan, a partner protein of dystrophin, can cause the most dramatic brain involvement of any muscular dystrophy. In these conditions, dystroglycan is not properly glycosylated (not given the sugar chains it needs to function). This leads to a range of brain abnormalities, from severe structural malformation to intellectual disability without visible brain changes.²⁸

In the most severe forms, the scaffolding cells that guide newly born neurons to their proper positions during fetal brain development cannot maintain the structural barrier at the brain’s surface. Neurons migrate past where they should stop, breaking through into the space surrounding the brain. The result is a condition called cobblestone lissencephaly, where the normally smooth and folded brain surface is disrupted by bumpy overgrowths of misplaced neurons. In the cerebellum, the reverse problem occurs: cells that should migrate inward from the surface become disorganized and fail to reach their destination.²⁹ The cognitive consequences of these migration failures can be profound, including severe intellectual disability and epilepsy. These conditions are rare but represent the extreme end of the brain involvement spectrum in muscular dystrophies.

Facioscapulohumeral Muscular Dystrophy and Neurosensory Features

Facioscapulohumeral muscular dystrophy (FSHD) does not typically cause cognitive impairment, but it does involve the nervous system in subtler ways. The best-documented features are hearing loss and retinal abnormalities. In a study of over 500 FSHD patients, about 13% had documented hearing loss, and roughly 4% had retinal abnormalities. Seizures were reported in about 2%, with a notably young median age at diagnosis.³⁰

The hearing loss is specifically a high-frequency pattern. Early audiometry studies comparing FSHD patients with their unaffected family members found that the difference in hearing between certain high frequencies was significantly greater in patients, independently in both ears.³¹ The retinal involvement typically takes the form of small vascular abnormalities: tiny widened blood vessels and microaneurysms visible on angiography. One study found these changes in about half of FSHD patients examined, though most cases were mild.³² These neurosensory features are recognized as part of the disease rather than coincidental, though they rarely dominate the clinical picture.

Prospects for Brain-Targeted Therapy

Current treatments for the brain effects of muscular dystrophy are primarily symptomatic: stimulant medications for ADHD, educational support for learning difficulties, and standard psychiatric care for anxiety or depression. But there is growing interest in whether the genetic therapies being developed for muscle disease could also reach the brain. In mouse models of Duchenne, restoring dystrophin expression in the brain through genetic approaches has improved behavioral outcomes, suggesting the brain deficits are at least partially reversible even after development.³³ In one experiment, exon skipping, a technique that tricks cells into producing a shorter but partially functional dystrophin, normalized the abnormal synaptic signaling in the hippocampus of mdx mice.¹⁶

The main obstacle is delivery. Most current gene therapies for Duchenne are designed to reach muscle, and the blood-brain barrier blocks many of them from entering the brain. Preclinical work is exploring direct delivery routes, including injection into the spinal fluid, as well as next-generation approaches that could cross the barrier after intravenous injection. None of these brain-targeted strategies has yet reached patients in clinical practice, but the animal data make a strong case that the brain deserves as much therapeutic attention as the muscles. For congenital dystroglycanopathies, the window may be even narrower: animal studies suggest that restoring dystroglycan function in the fetal stage can rescue cortical malformation, but the same intervention after birth has much less effect.²⁹ Timing, in other words, may matter as much as the therapy itself.